Linezolid Dosing in a Morbidly Obese Patient With MRSA Pneumonia

Abstract

Get full access to this article

View all access options for this article.

References

Rayner

Forrest

Meagher

. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 2003;42:1411-1423.

Bhalodi

Papasavas

Tishler

. Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother. 2013;57:1144-1149.

De Pascale

Fortuna

Tumbarello

. Linezolid plasma intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia:intermittent vs continuous administration. Intensive Care Med. 2015;41:103-110.

Muzevich

Lee

KB.

Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant Staphylococcus aureus pneumonia: case report and review of the literature. Ann Pharmacother. 2013;47:e25.

Corcione

Pagani

Baietto

. Pharmacokinetics of high dosage of linezolid in two morbidly obese patients. J Antimicrob Chemother. 2015;8:8-9.